Biosimilars will enter the US market soon, potentially lowering costs and increasing patient
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …

Biosimilar agents are biologic products that have been shown to be" highly similar" to an
already approved reference biologic product. Their integration into clinical practice has the …

Background: Biosimilars are developed to be highly similar to and treat the same conditions
as licensed biologics. As they are approved and their use becomes more widespread …

Biosimilars are biologic products that are highly similar, but not identical, to a licensed
reference (or" originator") biologic product. These agents have the potential to provide …

Importance Biosimilars are biological medicines that contain a highly similar version of the
active substance of an already approved biologic reference product. The availability of …

PURPOSE: Despite increasing availability of biosimilar cancer treatments, little is known
about oncologists' knowledge and concerns regarding biosimilar use in the United States …

Objective To summarize and review the clinical data of Food and Drug Administration (FDA)-
approved biosimilars for use in treatment of cancer and the current challenges health care …

Biosimilars of biologics used for cancer treatment and supportive care are expected to enter
the US market soon. Biosimilars will be highly similar to their reference products, but unlike …

35 Background: Despite the increasing availability of biosimilar cancer treatments, little is
known about oncologists' knowledge and concerns about biosimilar use in the United …

The introduction of alternative versions of biologic products, also known as biosimilars, into
the United States market has been gaining increasing visibility as patents for many agents …